Propanc Biopharma (PPCB) Liabilities and Shareholders Equity (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Liabilities and Shareholders Equity of $15.1 million for Q4 2025, up 19142.27% year-over-year from N/an in Q4 2024, and down 15.93% quarter-over-quarter from $18.0 million in Q3 2025.
Propanc Biopharma (PPCB) Liabilities and Shareholders Equity (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Liabilities and Shareholders Equity for 15 consecutive years, with $15.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity rose 19142.27% year-over-year to $15.1 million; the TTM figure through Dec 2025 stood at $75.2 million (up 29774.02% YoY), while the FY2025 annual figure was $19.6 million, up 27028.87% from the prior year.
- Liabilities and Shareholders Equity declined to $15.1 million in Q4 2025 per PPCB's latest filing, from $18.0 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $22.5 million in Q1 2025 and bottomed at $13101.0 in Q2 2021.
- Historically, Liabilities and Shareholders Equity has averaged $3.8 million across 5 years, with a median of $101138.0 in 2022.
- Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity tumbled 86.7% — and 2025, when it soared 60235.2%.
- Propanc Biopharma's Liabilities and Shareholders Equity stood at $110177.0 in 2021, then decreased by 1.96% to $108022.0 in 2022, then jumped by 123.94% to $241907.0 in 2023, then sank by 67.54% to $78533.0 in 2024, then jumped by 19142.27% to $15.1 million in 2025.
- Business Quant data shows PPCB's Liabilities and Shareholders Equity at $15.1 million in Q4 2025, $18.0 million in Q3 2025, and $19.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 15.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.11 Mn |
| Sep 30, 2025 | 17.98 Mn |
| Jun 30, 2025 | 19.63 Mn |
| Mar 31, 2025 | 22.53 Mn |
| Dec 31, 2024 | 78,533.00 |
| Sep 30, 2024 | 63,644.00 |
| Jun 30, 2024 | 72,365.00 |
| Mar 31, 2024 | 37,337.00 |
| Dec 31, 2023 | 241,907.00 |
| Sep 30, 2023 | 180,371.00 |
| Jun 30, 2023 | 60,328.00 |
| Mar 31, 2023 | 143,742.00 |
| Dec 31, 2022 | 108,022.00 |
| Sep 30, 2022 | 94,254.00 |
| Jun 30, 2022 | 81,651.00 |
| Mar 31, 2022 | 169,460.00 |
| Dec 31, 2021 | 110,177.00 |
| Sep 30, 2021 | 62,165.00 |
| Jun 30, 2021 | 13,101.00 |
| Mar 31, 2021 | 28,043.00 |